Assembly Biosciences Inc (NASDAQ:ASMB) – Stock analysts at Svb Leerink lifted their Q3 2019 EPS estimates for Assembly Biosciences in a report released on Tuesday, August 6th, according to Zacks Investment Research. Svb Leerink analyst G. Porges now forecasts that the biopharmaceutical company will post earnings per share of ($0.97) for the quarter, up from their previous estimate of ($1.19). Svb Leerink also issued estimates for Assembly Biosciences’ Q4 2019 earnings at ($0.89) EPS, FY2019 earnings at ($3.63) EPS, FY2020 earnings at ($4.98) EPS, FY2021 earnings at ($5.71) EPS and FY2022 earnings at ($3.89) EPS.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.41. Assembly Biosciences had a negative net margin of 622.25% and a negative return on equity of 46.33%. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.90 million.
ASMB stock opened at $12.28 on Thursday. The company has a current ratio of 9.20, a quick ratio of 9.20 and a debt-to-equity ratio of 0.06. The stock has a market cap of $329.11 million, a PE ratio of -3.09 and a beta of 1.44. The company has a 50-day moving average price of $13.28 and a 200 day moving average price of $16.76. Assembly Biosciences has a 12 month low of $11.49 and a 12 month high of $41.00.
A number of large investors have recently added to or reduced their stakes in ASMB. Bank of Montreal Can boosted its holdings in Assembly Biosciences by 2,084.1% during the second quarter. Bank of Montreal Can now owns 1,922 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 1,834 shares in the last quarter. Quantamental Technologies LLC raised its position in Assembly Biosciences by 16,941.2% during the second quarter. Quantamental Technologies LLC now owns 2,897 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 2,880 shares during the period. Aperio Group LLC acquired a new position in Assembly Biosciences during the second quarter worth $55,000. Tower Research Capital LLC TRC raised its position in Assembly Biosciences by 9,134.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,340 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,293 shares during the period. Finally, BNP Paribas Arbitrage SA raised its position in Assembly Biosciences by 87,340.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,372 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 4,367 shares during the period. 85.82% of the stock is currently owned by institutional investors.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Recommended Story: Real Estate Investment Trust (REIT) ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.